Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Hye Young Ji"'
Autor:
Min-Soo Kim, Yoo-Kyung Song, Ji-Soo Choi, Hye Young Ji, Eunsuk Yang, Joon Seok Park, Hyung Sik Kim, Min-Joo Kim, In-Kyung Cho, Suk-Jae Chung, Yoon-Jee Chae, Kyeong-Ryoon Lee
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 942 (2023)
Enavogliflozin is a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor approved for clinical use in South Korea. As SGLT2 inhibitors are a treatment option for patients with diabetes, enavogliflozin is expected to be prescribed in various pop
Externí odkaz:
https://doaj.org/article/580c6b225f774237b34dce9ed51ac759
Autor:
Dae Hee Shin, Ji Seok Yoo, Yongnam Lee, Sei-Ryang Oh, Hye Young Ji, Hyeon-Uk Jeong, Deok-Kyu Hwang, Min Gi Kim, Hye Suk Lee
Publikováno v:
Molecules, Vol 17, Iss 10, Pp 11990-12002 (2012)
Verproside, a catalpol derivative iridoid glycoside isolated from Pseudolysimachion rotundum var. subintegrum, is a biologically active compound with anti-inflammatory, antinociceptic, antioxidant, and anti-asthmatic properties. Twenty-one metabolite
Externí odkaz:
https://doaj.org/article/30ab205ed14f4ee898c360cbf09b8eea
Publikováno v:
Molecules, Vol 17, Iss 1, Pp 851-860 (2012)
Efavirenz is a non-nucleoside reverse transcriptase inhibitor used for the treatment of human immunodeficiency virus type 1 infections. Drug interactions of efavirenz have been reported due to in vitro inhibition of CYP2C9, CYP2C19, CYP3A4, and UDP-g
Externí odkaz:
https://doaj.org/article/b619f69801d1466eafe6e95b5cb57083
Publikováno v:
Molecules, Vol 16, Iss 8, Pp 6591-6602 (2011)
Corydaline is a bioactive alkaloid with various antiacetylcholinesterase, antiallergic, and antinociceptive activities found in the medicinal herb Corydalis Tubers. The inhibitory potential of corydaline on the activities of seven major human cytochr
Externí odkaz:
https://doaj.org/article/eb1f19f906f846649e4f97717308c8af
Publikováno v:
Molecules, Vol 15, Iss 9, Pp 6466-6475 (2010)
Eupatilin and jaceosidin are bioactive flavones found in the medicinal herbs of the genus Artemisia. These bioactive flavones exhibit various antioxidant, antiinflammatory, antiallergic, and antitumor activities. The inhibitory potentials of eupatili
Externí odkaz:
https://doaj.org/article/41e85f817ea54e379430b808d0d7e715
Autor:
Bikalpa Dhakal, Saugat Shiwakoti, Eun-Young Park, Ki-Woon Kang, Valérie B. Schini-Kerth, Sun-Hwa Park, Hye-Young Ji, Joon Seok Park, Ju-Young Ko, Min-Ho Oak
Publikováno v:
Scientific Reports. 13
Nano plastics (NPs) have been a significant threat to human health and are known to cause premature endothelial senescence. Endothelial senescence is considered one of the primary risk factors contributing to numerous cardiovascular disorders. Recent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9554d914cc125663f3762787bdeaffd
https://doi.org/10.1038/s41598-023-33086-2
https://doi.org/10.1038/s41598-023-33086-2
Publikováno v:
JCRPE, Vol 16, Iss 3, Pp 306-313 (2024)
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is defined as chronic hepatic steatosis and is becoming prevalent, along with the increasing trend for obesity in children and adolescents. A non-invasive and reliable tool is needed to differen
Externí odkaz:
https://doaj.org/article/48776587ce1847d7aca99984bc34bd70
Autor:
Minyeong Pang, So Yeon Jeon, Min-Koo Choi, Ji-Hyeon Jeon, Hye-Young Ji, Ji-Soo Choi, Im-Sook Song
Publikováno v:
Pharmaceutics; Volume 14; Issue 6; Pages: 1210
This study investigated the pharmacokinetics and tissue distribution of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor that is currently in phase three clinical trials. Enavogliflozin showed dose-proportional pharmacokinetics follow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d004ce8d519c561ea3d7548a9082a786
https://pubmed.ncbi.nlm.nih.gov/35745783
https://pubmed.ncbi.nlm.nih.gov/35745783
Autor:
Dong Kyun Kim, Hye Suk Lee, Won-Gu Choi, Sangkyu Lee, Ju-Hyun Kim, Hye-Young Ji, Ji-Soo Choi, Im-Sook Song
Publikováno v:
Pharmaceutics
Volume 12
Issue 9
Pharmaceutics, Vol 12, Iss 865, p 865 (2020)
Volume 12
Issue 9
Pharmaceutics, Vol 12, Iss 865, p 865 (2020)
DWP16001 is currently in a phase 2 clinical trial as a novel anti-diabetes drug for the treatment of type 2 diabetes by selective inhibition of sodium-glucose cotransporter 2. This in vitro study was performed to compare the metabolism of DWP16001 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d4cc4c308141a39fccdde577d3cc782
Publikováno v:
Pharmaceutics
Volume 12
Issue 3
Pharmaceutics, Vol 12, Iss 3, p 268 (2020)
Volume 12
Issue 3
Pharmaceutics, Vol 12, Iss 3, p 268 (2020)
Since sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced blood glucose level by inhibiting renal tubular glucose reabsorption mediated by SGLT2, we aimed to investigate the pharmacokinetics and kidney distribution of DWP16001, a novel SGLT2 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2610e63140d6959952a1ba75e5c0de2e